New England Journal of Medicine· 2018Q1

Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML

Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, Gail J. Roboz et al.

1,423citations
Q1SCImago
2018year

Short summary

Ivosidenib, a targeted inhibitor of mutant IDH1, achieved a 30.4% complete remission (CR) or CR with partial hematologic recovery rate in patients with relapsed/refractory AML, with median response durations of 8.2 months.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hematology

HematologyMedicine